Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096356 · ClinicalTrials.gov registry record · Phase 1
Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 236
- Enrollment target
NCT00096356: Completed Phase 1 study, sponsored by Wake Forest University Health Sciences.
NCT00096356 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 236 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (293% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096356, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 236 participants
- Enrollment target
Study Summary
RATIONALE: Coenzyme Q10 is a vitamin that may be effective in relieving fatigue and depression in women who are undergoing chemotherapy for breast cancer. PURPOSE: This randomized clinical trial is studying how well coenzyme Q10 works in relieving treatment-related fatigue in women with breast cancer.
Primary Outcome
POMS-F is the Profile of Mood States - fatigue scale. It ranges from 0 to 28; higher values indicate greater fatigue.
Interventions
- DIETARY_SUPPLEMENT CoQ10 & Vitamin E
- DIETARY_SUPPLEMENT Placebo & Vitamin E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2004-08-27 |
| Est. Completion | 2009-08-31 |
| Phase | Phase 1 |
What the finished NCT00096356 record still lists
NCT00096356 is an interventional study that assigns participants to a tested intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (293% higher).
The record links to 0 conditions, and to 2 interventions - of which CoQ10 & Vitamin E is the first listed.
NCT00096356 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00096356 about?
NCT00096356 is a clinical study titled "Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer". RATIONALE: Coenzyme Q10 is a vitamin that may be effective in relieving fatigue and depression in women who are undergoing chemotherapy for breast cancer. PURPOSE: This randomized clinical trial is studying how well coenzyme Q10 works in relieving treatment-related fatigue in women with breast canc...
What is the current status of trial NCT00096356?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 236 participants. The study started on 2004-08-27. Estimated completion is 2009-08-31.
What interventions are being tested in trial NCT00096356?
The interventions under investigation include: CoQ10 & Vitamin E (DIETARY_SUPPLEMENT), Placebo & Vitamin E (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00096356?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00096356's enrollment target sits among peer trials
236 212th of 2000 higher than 1,789 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04995341 · 236 participants · NA
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
- NCT05822362 · 236 participants · Phase 2
CBD for Individuals at Risk for Alzheimer's Disease
- NCT06200103 · 236 participants · Phase 2
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- NCT06494072 · 236 participants · Phase 4
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI